NCT04541706 2024-12-20
Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India
Pfizer
Phase 4 Completed
Clinical Trials
4 trialsNCT00652561 2024-09-03
Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer
Taiho Oncology, Inc.
Phase 2 Completed
NCT00330746 2012-05-18
CALC-1
National Cancer Institute, Naples
Phase 2 Completed
NCT00319514 2008-03-12
Weekly Versus 3-Weekly Docetaxel Plus Cisplatin for Advanced NSCLC
Gachon University Gil Medical Center
Phase 2 Completed